Literature DB >> 9555760

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

J Lazarou1, B H Pomeranz, P N Corey.   

Abstract

OBJECTIVE: To estimate the incidence of serious and fatal adverse drug reactions (ADR) in hospital patients. DATA SOURCES: Four electronic databases were searched from 1966 to 1996. STUDY SELECTION: Of 153, we selected 39 prospective studies from US hospitals. DATA EXTRACTION: Data extracted independently by 2 investigators were analyzed by a random-effects model. To obtain the overall incidence of ADRs in hospitalized patients, we combined the incidence of ADRs occurring while in the hospital plus the incidence of ADRs causing admission to hospital. We excluded errors in drug administration, noncompliance, overdose, drug abuse, therapeutic failures, and possible ADRs. Serious ADRs were defined as those that required hospitalization, were permanently disabling, or resulted in death. DATA SYNTHESIS: The overall incidence of serious ADRs was 6.7% (95% confidence interval [CI], 5.2%-8.2%) and of fatal ADRs was 0.32% (95% CI, 0.23%-0.41%) of hospitalized patients. We estimated that in 1994 overall 2216000 (1721000-2711000) hospitalized patients had serious ADRs and 106000 (76000-137000) had fatal ADRs, making these reactions between the fourth and sixth leading cause of death.
CONCLUSIONS: The incidence of serious and fatal ADRs in US hospitals was found to be extremely high. While our results must be viewed with circumspection because of heterogeneity among studies and small biases in the samples, these data nevertheless suggest that ADRs represent an important clinical issue.

Entities:  

Mesh:

Year:  1998        PMID: 9555760     DOI: 10.1001/jama.279.15.1200

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  1038 in total

1.  Herbal medicine: a practical guide to safety and quality assurance.

Authors:  M D Rotblatt
Journal:  West J Med       Date:  1999-09

2.  Spontaneous reporting--of what? Clinical concerns about drugs.

Authors:  I R Edwards
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 3.  Science, medicine, and the future: Pharmacogenetics.

Authors:  C R Wolf; G Smith; R L Smith
Journal:  BMJ       Date:  2000-04-08

4.  Using information technology to reduce rates of medication errors in hospitals.

Authors:  D W Bates
Journal:  BMJ       Date:  2000-03-18

5.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres.

Authors:  P Pouyanne; F Haramburu; J L Imbs; B Bégaud
Journal:  BMJ       Date:  2000-04-15

6.  Rational or rationed medicine? The promise of genetics for improved clinical practice.

Authors:  R Fears; D Roberts; G Poste
Journal:  BMJ       Date:  2000-04-01

7.  Academic detailing improves identification and reporting of adverse drug events.

Authors:  R G Schlienger; T F Lüscher; R A Schoenenberger; W E Haefeli
Journal:  Pharm World Sci       Date:  1999-06

Review 8.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 9.  ["Clinically significant" new drug interactions].

Authors:  U Fuhr
Journal:  Med Klin (Munich)       Date:  1999-02-15

10.  Adverse reporting on adverse reactions.

Authors:  N Bains; D Hunter
Journal:  CMAJ       Date:  1999-02-09       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.